On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine

Janina Baranowska-Kortylewicz, Glenn V. Dalrymple, Katherine A. Harrison, Karen P. Holdeman, John G Sharp, Samuel Monroe Cohen, Robert P. Lieberman, Martin H. Schneiderman, Sydney R. Clausen, Debra Hoffman, Jing Lai, G. Sue Schneiderman, Lynn Helseth

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i.v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i.v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.

Original languageEnglish (US)
Pages (from-to)925-933
Number of pages9
JournalActa Oncologica
Volume35
Issue number7
DOIs
Publication statusPublished - Jan 1 1996

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this